PE20121643A1 - Polipeptidos del factor ix modificados y usos de los mismos - Google Patents
Polipeptidos del factor ix modificados y usos de los mismosInfo
- Publication number
- PE20121643A1 PE20121643A1 PE2012000114A PE2012000114A PE20121643A1 PE 20121643 A1 PE20121643 A1 PE 20121643A1 PE 2012000114 A PE2012000114 A PE 2012000114A PE 2012000114 A PE2012000114 A PE 2012000114A PE 20121643 A1 PE20121643 A1 PE 20121643A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptide
- remains
- factor
- polypeptides
- conjugate
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 229960004222 factor ix Drugs 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23055109P | 2009-07-31 | 2009-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121643A1 true PE20121643A1 (es) | 2012-11-25 |
Family
ID=43529743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000114A PE20121643A1 (es) | 2009-07-31 | 2010-08-02 | Polipeptidos del factor ix modificados y usos de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120164130A1 (enExample) |
| EP (1) | EP2461821A4 (enExample) |
| JP (1) | JP2013500726A (enExample) |
| KR (1) | KR20120060209A (enExample) |
| CN (1) | CN102573890A (enExample) |
| AU (1) | AU2010278721A1 (enExample) |
| BR (1) | BR112012002072A2 (enExample) |
| CA (1) | CA2769258A1 (enExample) |
| CL (1) | CL2012000238A1 (enExample) |
| CR (1) | CR20120052A (enExample) |
| CU (3) | CU20120018A7 (enExample) |
| DO (1) | DOP2012000030A (enExample) |
| EA (1) | EA201290069A1 (enExample) |
| EC (1) | ECSP12011637A (enExample) |
| GT (1) | GT201200023A (enExample) |
| IN (1) | IN2012DN00908A (enExample) |
| MX (1) | MX2012001346A (enExample) |
| PE (1) | PE20121643A1 (enExample) |
| SG (1) | SG178119A1 (enExample) |
| WO (1) | WO2011014890A1 (enExample) |
| ZA (1) | ZA201200716B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| TR201813067T4 (tr) | 2008-09-15 | 2018-09-21 | Uniqure Biopharma B V | Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem. |
| EP3093029A1 (en) | 2009-07-27 | 2016-11-16 | Baxalta GmbH | Blood coagulation protein conjugates |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| TR201908836T4 (tr) * | 2010-07-30 | 2019-07-22 | Baxalta GmbH | Oksim bağına yönelik nükleofilik katalizörler. |
| BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
| RU2617764C2 (ru) * | 2011-12-19 | 2017-04-26 | Дилафор Аб | Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение |
| CA2892038C (en) * | 2012-11-20 | 2021-12-28 | Darrel W. Stafford | Methods and compositions for modified factor ix proteins |
| US10105447B2 (en) * | 2013-03-13 | 2018-10-23 | Elanco Us Inc. | Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide |
| TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| CN109789181A (zh) * | 2016-07-27 | 2019-05-21 | 费城儿童医院 | 用于调节因子ix功能的组合物和方法 |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| AU2019360270B2 (en) | 2018-10-18 | 2025-08-07 | Intellia Therapeutics, Inc. | Compositions and methods for expressing factor IX. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044982A1 (en) * | 2001-04-25 | 2003-03-06 | Kenneth Chien | Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| MXPA06006023A (es) * | 2003-12-03 | 2006-08-23 | Neose Technologies Inc | Factor ix glicopegilado. |
| EP2423307A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
| US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
-
2010
- 2010-08-02 JP JP2012523129A patent/JP2013500726A/ja active Pending
- 2010-08-02 KR KR1020127005191A patent/KR20120060209A/ko not_active Withdrawn
- 2010-08-02 CN CN2010800431356A patent/CN102573890A/zh active Pending
- 2010-08-02 IN IN908DEN2012 patent/IN2012DN00908A/en unknown
- 2010-08-02 MX MX2012001346A patent/MX2012001346A/es not_active Application Discontinuation
- 2010-08-02 AU AU2010278721A patent/AU2010278721A1/en not_active Abandoned
- 2010-08-02 EA EA201290069A patent/EA201290069A1/ru unknown
- 2010-08-02 PE PE2012000114A patent/PE20121643A1/es not_active Application Discontinuation
- 2010-08-02 EP EP10805185.5A patent/EP2461821A4/en not_active Withdrawn
- 2010-08-02 BR BR112012002072A patent/BR112012002072A2/pt not_active IP Right Cessation
- 2010-08-02 US US13/388,288 patent/US20120164130A1/en not_active Abandoned
- 2010-08-02 SG SG2012005757A patent/SG178119A1/en unknown
- 2010-08-02 WO PCT/US2010/044177 patent/WO2011014890A1/en not_active Ceased
- 2010-08-02 CA CA2769258A patent/CA2769258A1/en not_active Abandoned
-
2012
- 2012-01-27 DO DO2012000030A patent/DOP2012000030A/es unknown
- 2012-01-30 CU CU20120018A patent/CU20120018A7/es unknown
- 2012-01-30 GT GT201200023A patent/GT201200023A/es unknown
- 2012-01-30 EC EC2012011637A patent/ECSP12011637A/es unknown
- 2012-01-30 ZA ZA2012/00716A patent/ZA201200716B/en unknown
- 2012-01-30 CL CL2012000238A patent/CL2012000238A1/es unknown
- 2012-01-30 CR CR20120052A patent/CR20120052A/es unknown
-
2013
- 2013-04-19 CU CU2013000058A patent/CU20130058A7/es unknown
- 2013-04-19 CU CU2013000057A patent/CU20130057A7/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20120018A7 (es) | 2012-06-21 |
| MX2012001346A (es) | 2012-02-17 |
| EP2461821A4 (en) | 2013-07-03 |
| CU20130058A7 (es) | 2013-06-28 |
| BR112012002072A2 (pt) | 2016-11-08 |
| ECSP12011637A (es) | 2012-02-29 |
| CN102573890A (zh) | 2012-07-11 |
| EA201290069A1 (ru) | 2012-07-30 |
| WO2011014890A1 (en) | 2011-02-03 |
| CR20120052A (es) | 2012-06-04 |
| CU20130057A7 (es) | 2013-06-28 |
| JP2013500726A (ja) | 2013-01-10 |
| GT201200023A (es) | 2014-01-27 |
| EP2461821A1 (en) | 2012-06-13 |
| ZA201200716B (en) | 2013-07-31 |
| SG178119A1 (en) | 2012-03-29 |
| US20120164130A1 (en) | 2012-06-28 |
| DOP2012000030A (es) | 2012-02-29 |
| IN2012DN00908A (enExample) | 2015-04-03 |
| CA2769258A1 (en) | 2011-02-03 |
| AU2010278721A1 (en) | 2012-02-16 |
| CL2012000238A1 (es) | 2012-10-05 |
| KR20120060209A (ko) | 2012-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121643A1 (es) | Polipeptidos del factor ix modificados y usos de los mismos | |
| PE20091931A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
| CO6351745A2 (es) | Polipéptidos g-csf bovinos modificados y sus usos | |
| DOP2010000311A (es) | Polipeptidos modificados del factor ix y usos de los mismos | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| WO2010043650A3 (en) | Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry | |
| CL2015000060A1 (es) | Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia. | |
| UY33578A (es) | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS | |
| ES2721882T3 (es) | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas | |
| PH12017500866A1 (en) | Targeted xten conjugate compositions and methods of making same | |
| AR084053A1 (es) | Agente terapeutico que induce citotoxicidad | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| BR112012015461A2 (pt) | polipeptídeos de somatotropina boviina modificados e seus usos | |
| PE20120021A1 (es) | Mutantes fgf21 | |
| MX2014006396A (es) | Vacunas contra el virus de la influenza y sus usos. | |
| MX2017003590A (es) | Composiciones que comprenden celulas recombinantes de bacillus y un insecticida. | |
| CO6501124A2 (es) | Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas | |
| CL2009000619A1 (es) | Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer. | |
| CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
| BRPI1014978A2 (pt) | método de tratamento do câncer e composição farmacêutica. | |
| CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas | |
| MY160922A (en) | Polyethylene glycol conjugated blood coagulation factor vii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |